Methods for high-throughput screening of sirtuin mutants, sirtuin mutants and their applications

By constructing a sirtuin mutant library using error-prone PCR and combining it with AMC fluorescence method, a simple, universal, and sensitive method for high-throughput screening of sirtuin mutants was achieved. This solved the problem of sirtuin enzyme activity detection in existing technologies, simplified the operation process, and improved screening efficiency.

CN117721177BActive Publication Date: 2026-11-17SHENZHEN INST OF ADVANCED TECH CHINESE ACAD OF SCI
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202211127488.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-09-16
Publication Date
2026-11-17
Estimated Expiration
2042-09-16

AI Technical Summary

Technical Problem

The lack of efficient and accurate methods for detecting sirtuin enzyme activity in current technologies makes it difficult to develop drugs targeting sirtuin. Furthermore, existing methods suffer from cumbersome operation and enzyme inactivation issues in high-throughput screening.

Method used

A sirtuin mutant library was constructed using error-prone PCR, and deacylation activity was determined using high-throughput AMC fluorescence assay. High-throughput screening was performed through a seamless link between bacterial protein expression-lysis-detection, simplifying the process to three steps: library construction, lysis, and detection.

Benefits of technology

It enables simple, universal, and sensitive high-throughput screening of sirtuin mutants, allowing direct detection of enzyme activity in vivo, without being limited to specific environments, simplifying the operation process and improving screening efficiency.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117721177B_ABST
    Figure CN117721177B_ABST
Patent Text Reader

Abstract

This invention relates to a high-throughput screening method for sirtuin mutants and its application. The screening method for sirtuin mutants includes the following steps: constructing a sirtuin mutant library using error-prone PCR technology; lysing each mutant in the sirtuin mutant library, separating the solid and liquid phases, and collecting the lysate supernatant; determining the sirtuin deacylation activity of the lysate supernatant using AMC fluorescence assay to obtain the desired sirtuin mutant with the desired deacylation activity. Using the above-mentioned screening method for sirtuin mutants, deacylation enzyme sirtuin mutants can be screened simply, in high throughput, and reproducibly.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of biotechnology, and in particular to a method for high-throughput screening of sirtuin mutants, as well as sirtuin mutants and their applications. Background Technology

[0002] Sirtuins are a class of NAD+-based protein deacetylation enzymes widely found in bacteria, archaea, and eukaryotes, participating in the regulation of a series of important biological processes, including gene transcription, chromosome segregation, RNA splicing, cell metabolism, apoptosis, and energy metabolism. In addition to deacetylation activity, sirtuins have also been reported to possess other enzymatic activities, such as desuccinylation, demyristylation, and denonylation.

[0003] Sirtuin deacylation regulation is closely related to obesity, aging, cancer, neurodegenerative diseases, and cardiovascular diseases. In recent years, the crystal structures of sirtuin in different species, such as humans, yeast, and *E. coli*, have been resolved. However, due to a lack of systematic understanding of the molecular mechanisms of sirtuin enzyme activity, the key regulatory sites of sirtuin deacylation activity are not yet fully understood. Furthermore, no drugs targeting sirtuin have been approved for marketing to date. A major reason for this is the lack of an efficient and accurate detection method for sirtuin enzyme activity. Currently, the main methods for detecting sirtuin enzyme activity include isotope labeling, Western blotting, high-performance liquid chromatography (HPLC), and fluorescence methods. Isotope labeling is no longer commonly used due to its cumbersome operation and potential safety concerns. Immunoblotting and high-performance liquid chromatography (HPLC) are only suitable for routine in vitro enzyme activity characterization. While coumarin-based and FRET-based fluorescence methods can be applied to large-scale determination of sirtuin enzyme activity, current research still requires in vitro expression and purification of sirtuin protein, which is labor-intensive. Furthermore, direct cleavage of sirtuin synthesized in vivo often leads to enzyme inactivation, thus limiting the direct application of these methods in high-throughput enzyme activity detection. Currently, fluorescence methods are only used for large-scale in vitro screening of sirtuin protein inhibitors or activators. Therefore, developing a high-throughput screening method for sirtuin deacylation enzyme activity is a current technical challenge and a prerequisite for in-depth research into the specificity of sirtuin enzyme activity and the discovery of its in vivo functional regulation. Summary of the Invention

[0004] Therefore, it is necessary to provide a simple, universal, and sensitive high-throughput screening method for sirtuin mutants.

[0005] In addition, a sirtuin mutant and its application are also provided.

[0006] A method for screening sirtuin mutants includes the following steps: A library of sirtuin mutants was constructed using error-prone PCR techniques. Each mutant in the sirtuin mutant library was lysed, solid-liquid separation was performed, and the lysate supernatant was collected. The sirtuin deacylation activity of the lysed supernatant was determined by high-throughput AMC fluorescence method to obtain the sirtuin mutant with the desired deacylation activity.

[0007] The above-described method for screening sirtuin mutants utilizes error-prone PCR to obtain a sirtuin protein mutant library. Then, the heterologously expressed sirtuin protein mutants are lysed to obtain crude enzyme solutions. Finally, the deacylation activity of the sirtuin mutants is detected in situ using an AMC fluorescent group-based release method. This method, consisting of library construction, lysis, and detection, allows for high-throughput screening of sirtuin protein mutants. The steps are simple, as lysis directly releases in vivo synthesized sirtuin, which is then detected by AMC fluorescence. This method is universal and can screen for the enzyme activity of different sirtuins, not limited to specific functions of sirtuin under specific conditions. More importantly, this method combines error-prone PCR and AMC fluorescence, enabling high-throughput screening of artificially synthesized sirtuin mutants through a seamless connection between bacterial protein expression, lysis, and detection. Using this method, a simple, universal, and sensitive high-throughput screening method for deacylated sirtuin mutants can be achieved.

[0008] In one embodiment, the sirtuin mutant library is constructed using an initial sirtuin gene, the initial sirtuin gene comprising linked critical and non-critical region segments. The steps for constructing the sirtuin mutant library include: Error-prone PCR was performed using a plasmid carrying the initial sirtuin gene as a template to obtain a mutant fragment, which is the critical region fragment where a point mutation has occurred. Using a plasmid carrying an expression vector as a template, PCR amplification was performed under the action of a high-fidelity enzyme to obtain an expression vector fragment. The expression vector is used to express the initial sirtuin. The expression vector fragment is composed of expression and replication elements for expressing the sirtuin protein. The resistance gene of the plasmid carrying the expression vector is different from that of the plasmid carrying the initial sirtuin gene. The mutant fragment and the expression vector fragment were recombined and ligated, and then transferred into host cells to obtain the sirtuin mutant library.

[0009] In one embodiment, error-prone PCR is performed using a first primer pair, the sequences of which are shown in SEQ ID No. 1 to SEQ ID No. 2.

[0010] In one embodiment, in the step of using a plasmid carrying the initial sirtuin gene as a template for PCR amplification under the action of a high-fidelity enzyme, a second primer pair is used for PCR amplification, the sequence of which is shown in SEQ ID No. 3~SEQ ID No. 4.

[0011] In one embodiment, a mutant library with 10 times theoretical coverage is constructed at a mutation frequency of 1-4 bases / kb, which can screen for amino acid sites in the key region of sirtuin. The mutant library contains 2,000-6,000 clones.

[0012] In one embodiment, in the step of lysing each mutant in the sirtuin mutant library, cell lysis buffer is used for lysis. The cell lysis buffer includes: a non-denaturing detergent and a buffer solution with pH 7-8. The volume ratio of the cell lysis buffer to the bacterial solution containing the test cells is 1:20-1:40. The lysis temperature is 20℃-30℃ and the lysis time is 10 min-20 min.

[0013] In one embodiment, the step of determining the sirtuin deacylation activity of the lysis supernatant using AMC fluorescence method includes: The AMC peptide reaction solution was mixed with the lysis supernatant and reacted at 37°C and 200 rpm to 300 rpm for 1 h to obtain the first treatment solution. The AMC peptide reaction solution contained AMC peptides with acyl modification and the final concentration of the AMC peptides was 100 μM to 500 μM. Add 2× stop solution to the first treatment solution and let it stand at 25 ℃~37 ℃ for 1 h~1.5 h to obtain the second treatment solution. The stop solution includes 2.0 mg / mL~5.0 mg / mL trypsin and 2× Tris buffer containing 2 mM~6 mM NAM. The fluorescence intensity of the second treatment solution was detected at an excitation wavelength of 360 nm and an emission wavelength of 460 nm. The deacylation activity of sirtuin in the test cells was determined based on the fluorescence intensity of the second treatment solution.

[0014] In one embodiment, the acyl modification in the AMC peptide with acyl modification is acetyl modification, succinyl modification, myristyl modification, nonanoyl modification, or long-chain fatty acyl modification.

[0015] In one embodiment, the AMC peptide is a lysine-acylated peptide with a BOC protecting group and labeled with AMC.

[0016] A sirtuin mutant was prepared using the sirtuin mutant screening method described above.

[0017] In one embodiment, it is obtained by mutation at at least one of the following sites of wild-type sirtuin: alanine at position 76, phenylalanine at position 91, histidine at position 147, cysteine ​​at position 155, and proline at position 185.

[0018] In one embodiment, the alanine at position 76 undergoes one of the following mutations: A76P or A76V. The phenylalanine at position 91 undergoes one of the following mutations: F91L or F91S; One of the following mutations occurs at histidine position 147: H147L or H147Y; The cysteine ​​at position 155 undergoes one of the following mutations: C155R, C155S, or C155Y. One of the following mutations occurs at position 185 of the proline: P185L or P185T.

[0019] The application of the above-mentioned sirtuin mutant in altering deacylation enzyme activity. Attached Figure Description

[0020] Figure 1 This is a schematic diagram of the AMC fluorescence detection principle. Figure 2 Flowchart for building a mutant library; Figure 3 Gel electrophoresis images of the mutated fragment and the backbone fragment; Figure 4 This is a diagram of the sequencing results from Example 1; Figure 5 This is a gel electrophoresis image of the lysis supernatant; Figure 6 The image shows the fluorescence detection results of the reaction between BL21 cleavage products and peptides. Figure 7 A graph showing the fluorescence detection results of the reaction between purified sirtuin protein or sirtuin-containing cell lysate supernatant and substrate; Figure 8 Example image of fluorescence detection results for mutant library; Figure 9 This is a diagram showing the enzyme activity and site information of a mutant library detected by fluorescence. Figure 10Diagram showing the regulatory sites of sirtuin enzyme activity; Figure 11 Cell lysis buffer and AMC-peptide Ac or AMC-peptide Su The fluorescence detection results of the peptide reaction; Figure 12 The graph shows the effect of the lysis buffer on the enzyme activity of STM1221 and SIRT2. Detailed Implementation

[0021] To make the above-mentioned objects, features, and advantages of the present invention more apparent and understandable, the specific embodiments of the present invention will be described in detail below with reference to specific examples and accompanying drawings. Many specific details are set forth in the following description to provide a thorough understanding of the present invention. However, the present invention can be practiced in many other ways different from those described herein, and those skilled in the art can make similar modifications without departing from the spirit of the present invention. Therefore, the present invention is not limited to the specific embodiments disclosed below.

[0022] One embodiment of this application provides a method for screening sirtuin mutants, including the following steps S210~S230: S210. Construct a sirtuin mutant library using error-prone PCR technology.

[0023] Error-prone PCR is a method for constructing a library of random point mutants of proteins. It reduces the accuracy of DNA replication by using a low-fidelity DNA polymerase in PCR and adjusting the PCR reaction conditions, thereby achieving point mutations in genes. After the mutation is introduced into the gene, the corresponding amino acid is altered, thus affecting the structure and function of the target protein. Error-prone PCR generates a large number of mutant products, which are then cloned and ligated into expression vectors to create a library of random point mutants of the target protein. Using error-prone PCR can increase the size of the mutant library, thereby increasing its coverage and improving screening accuracy.

[0024] In one embodiment, an initial sirtuin is used to construct a sirtuin mutant library. The initial sirtuin gene includes key and non-key region segments. The initial sirtuin is the sirtuin that needs to be mutated. The initial sirtuin is not limited and can be a wild-type sirtuin or other sirtuins that have already been mutated and need to be mutated again.

[0025] The critical region is the area where active sites (i.e., sites that affect enzyme activity) may be located. The non-critical region is the area other than the critical region.

[0026] Specifically, such as Figure 2 ( Figure 2 As shown in the flowchart for constructing a mutant library, the steps for constructing a sirtuin mutant library using error-prone PCR technology include S211~S213: S211. Using a plasmid carrying the initial sirtuin gene as a template, error-prone PCR was performed to obtain the mutant fragment, which is a key region fragment where point mutations occur.

[0027] The mutated fragments are key region fragments with 1 to 4 point mutations. It should be noted that by controlling the amount of template in error-prone PCR, DNA fragments with 1-4 point mutations in the key sirtuin region can be amplified in each product.

[0028] The plasmid carrying the primordial sirtuin gene is the pET28a-sirtuin plasmid, which is resistant to kanamycin (Kan). This plasmid is capable of expressing primordial sirtuin.

[0029] Error-prone PCR was performed using the first primer pair. The sequences of the first primer pair are shown in SEQ ID No. 1 to SEQ ID No. 2. Specifically, the sequence shown in SEQ ID No. 1 is ggaaatgatggaaaacccaaga, and the sequence shown in SEQ ID No. 2 is ccgacttggcttggctcaag.

[0030] Specifically, the EP-PCR system formulation is shown in Table 2.

[0031] Table 2 EP-PCR system formulation

[0032] In a specific example, using pET28a-sirtuin plasmid as a template, the GeneMorph II Random Mutagenesis Kit (Agilent) was used to amplify DNA fragments (i.e., mutant fragments) with 1-4 point mutations in the key sirtuin region in each product by controlling the amount of template.

[0033] S212. Using the plasmid carrying the expression vector as a template, PCR amplification is performed under the action of a high-fidelity enzyme to obtain the expression vector fragment. The expression vector is used to express the initial sirtuin. The expression vector fragment is composed of expression and replication elements for expressing the sirtuin protein. The resistance gene of the plasmid carrying the expression vector is different from that of the plasmid carrying the initial sirtuin gene.

[0034] The plasmid carrying the expression vector is the pTEV5-sirtuin plasmid, which is resistant to ampicillin (Amp). This plasmid is able to express primordial sirtuin.

[0035] In the step of PCR amplification using a plasmid carrying the expression vector as a template and under the action of a high-fidelity enzyme, a second primer pair is used for PCR amplification. The sequences of the second primer pairs are shown in SEQ ID No. 3 to SEQ ID No. 4. Specifically, the sequence shown in SEQ ID No. 3 is cttgagccaagccaagtcgg, and the sequence shown in SEQ ID No. 4 is tcttgggttttccatcatttcc.

[0036] In a specific example, using pTEV5-sirtuin as a template, a high-fidelity enzyme was used to amplify the sirtuin fragment along with the expression vector, excluding the key region, and the template was eliminated with DpnI to obtain the vector fragment.

[0037] It should be noted that the order of S211 and S212 is not limited. S211 can be performed first and then S212, or S212 can be performed first and then S211, or S211 and S212 can be performed simultaneously.

[0038] S213. After recombination and ligation of the mutant fragment and the expression vector fragment, the mutant fragment is transferred into the host cell to obtain the sirtuin mutant library.

[0039] In this method, recombinase is used to ligate the mutant fragment and the expression vector fragment.

[0040] The host cell is a competent host cell. Specifically, it can be a competent DH5α or a competent BL21, or other competent host cells.

[0041] In a specific example, the PCR product fragment, after purification, was ligated with recombinase and transformed into DH5α competent cells. Positive clones, i.e., target clones, were selected using ampicillin resistance screening. Approximately 10 clones were selected for sequencing to check for random point mutations in key regions and whether the number of mutations met the requirements. Based on the results, the initial template concentration was adjusted to achieve the desired mutation frequency in the obtained clones. Because the fragment ligation products (mutant fragment and vector fragment recombinant ligation product) in this example are difficult to directly and efficiently transform into BL21, this protocol first transforms the recombinant product into DH5α, then extracts plasmids from DH5α mixed plaques and transforms them into BL21. BL21 clones successfully grown on ampicillin plates were then randomly selected for sequencing to check whether the mutation results met expectations. It should be noted that if the fragment ligation product can be directly transformed into BL21, the step of transforming into DH5α can be omitted.

[0042] In one specific example, the enzyme used to construct a sirtuin mutant library by performing error-prone PCR mutations on the selected sirtuin gene was the enzyme from Agilent's GeneMorph II Random Mutagenesis Kit.

[0043] S220, each mutant in the lysitin mutant library was lysed, solid-liquid separation was performed, and the lysed supernatant was collected.

[0044] The cell lysis was performed using a cell lysis buffer, which included a non-denaturing detergent and a buffer solution at pH 7-8. This cell lysis buffer can lyse cells containing sirtuin, and the resulting lysis products can be used for AMC fluorescence detection of sirtuin deacylation enzyme activity without purification.

[0045] Furthermore, the cell lysis buffer includes 0.5% to 2% by mass of a non-denaturing detergent, 100mM to 200mM of salts, and a buffer solution with a pH of 7 to 8.

[0046] Studies have found that the cell lysis buffer containing 0.5%–2% (w / w) non-denaturing detergent, 100 mM–200 mM salts, and a pH of 7–8 can lyse cells containing sirtuin. The resulting lysis products can be used for AMC fluorescence detection of sirtuin deacylation enzyme activity without purification. The procedure is simple and allows for enzyme activity screening of different sirtuins, not limited to specific functions of sirtuin under specific conditions. Experimental verification showed that using the cell lysis buffer developed in this study, lysis products from BL21 cells transformed with STM1221 reacted with AMC peptides to produce fluorescence, while lysis products from BL21 cells not transformed with STM1221 did not produce fluorescence when mixed with AMC peptides, indicating high specificity for enzyme activity detection.

[0047] The non-denaturing detergent is at least one of NP-40 (i.e., ethyl phenyl polyethylene glycol), sodium oxycholate, and Triton X-100 (polyethylene glycol octylphenyl ether). The addition of the non-denaturing detergent gently lyses cells, reducing its impact on the activity of released intracellular enzymes. Further, the mass percentage of the non-denaturing detergent is 0.5% to 2%. Even further, the mass percentage of the non-denaturing detergent is 0.5% to 1.5%.

[0048] The buffer solution is a 25 mM to 50 mM Tris-HCl buffer. This buffer solution can both aid in cell lysis and protect the activity of enzymes released during cell lysis.

[0049] The salts are NaCl or KCl. Sodium chloride and potassium chloride can achieve a certain concentration in the solution, maintain osmotic pressure, and ensure a certain ionic strength to stabilize proteins. Generally, NaCl, the same component as physiological saline, is used.

[0050] In one specific example, the cell lysis buffer comprises: 1% NP-40, 150 mM NaCl, pH 7.6, and 25 mM Tris-HCl buffer. This cell lysis buffer gently lyses cells, minimizing the impact on the activity of released intracellular enzymes.

[0051] The step of lysing the sirtuin mutant library using cell lysis buffer includes: mixing the cell lysis buffer with a bacterial culture containing cells from the sirtuin mutant library at a ratio of 1:20 to 1:40, and shaking at 300 rpm for 10 to 20 minutes at a lysis temperature of 20°C to 30°C.

[0052] The solid-liquid separation method is centrifugation. In a specific example, the centrifugation conditions are 4000 rpm and 4 ℃ for 10 min. It should be noted that the solid-liquid separation method is not limited to centrifugation; other solid-liquid separation methods, such as filtration, can also be used.

[0053] In a specific example, the steps of S220 include: picking BL21 clones into 96-well plates and incubating overnight at 37 °C and 800 rpm. Then, the saturated bacterial culture was transferred 1:20 to new 96-well plates and incubated for another 1.5-2 hours until the OD reached 0.4. At this point, IPTG was added to a final concentration of 0.3 mM, and sirtuin protein expression was induced at 25 °C. After 16 hours, the plates were centrifuged at 4000 rpm and 4 °C for 10 min to collect the cells. Then, 10 μL of mild cell lysis buffer (pH 7.6) containing a non-denaturing detergent and 25 mM Tris-HCl buffer was added to each well of the 96-well plate. The plates were shaken at 300 rpm for 10 min to obtain cell lysis products. Finally, the plates were centrifuged at 4000 rpm and 4 °C for 10 min to obtain the lysis supernatant containing the target sirtuin protein.

[0054] S230. The sirtuin deacylation activity of the lysate supernatant was determined by AMC fluorescence method to obtain the sirtuin mutant with the desired deacylation activity.

[0055] 7-Amino-4-methylcoumarin (AMC) is a fluorescent labeling reagent for peptides, widely used in protease research. When measuring sirtuin activity using the AMC fluorescence method, the coumarin amine of AMC undergoes a condensation reaction with the carboxyl group of the C-terminal lysine residue of the peptide molecule to form an amide bond, synthesizing an AMC-modified peptide molecule (the principle of AMC fluorescence detection is as follows). Figure 1 (As shown). If there is a complete acylation modification group on the lysine side chain, trypsin cannot hydrolyze the amide bond to release AMC due to steric hindrance. However, when sirtuin removes the acylation modification on the lysine side chain, the steric hindrance disappears, and the resulting unmodified peptide is subsequently cleaved by trypsin, releasing AMC. Since AMC fluoresces under 360 nm excitation and 460 nm emission, and the amount of AMC released is proportional to the enzyme activity of sirtuin, the enzyme activity of sirtuin can be quantitatively characterized by reading the fluorescence data.

[0056] Specifically, steps S230 include S231-S233: S231. Mix the AMC peptide reaction solution with the above lysis supernatant and react at 37°C and 200 rpm to 300 rpm for 1 h to obtain the first treatment solution.

[0057] The AMC peptide reaction solution contains AMC peptides with acyl modifications. The final concentration of the AMC peptides ranges from 100 μM to 500 μM. Specifically, the final concentration of the AMC peptides is 200 μM. The volume ratio of the AMC peptide reaction solution to the lysis supernatant is 1:1. This volume ratio facilitates sampling and loading.

[0058] In one embodiment, the AMC peptide is a synthetic peptide with lysine acylation modification and AMC labeling, protected by a BOC group.

[0059] In one embodiment, the acyl modification in the AMC peptide is acetyl, succinyl, myristyl, nonanoyl, or a long-chain fatty acyl. It should be noted that using AMC peptides with different acyl modifications allows for the determination of different deacylation enzyme activities of sirtuin. It should also be noted that the acyl modification is not limited to the acyl modifications mentioned above; other acyl modifications are also possible. AMC-peptide peptides with different acyl modifications can be used depending on the desired deacylation enzyme activity to be measured.

[0060] In a specific example, the AMC peptide with acyl modification is called AMC-peptide. Ac(i.e., acetyl-modified AMC-peptide peptide). The specific steps in S231 are: add AMC-peptide to each well of a 384-well plate. Ac The reaction solution consisted of 10 μL, including 2 μL of 10×Tris buffer (0.5 M Tris-HCl, pH 8.0, 1.37 M NaCl, 27 mM KCl, 10 mM MgCl2), and 1 μL of 20 mM NAD2. + 0.8 μL 5 mM AMC-peptide Ac 6.2 μL ddH2O was added. Then, 10 μL of the obtained sirtuin protein lysis supernatant was added, bringing the total volume to 20 μL and the final peptide concentration to 200 μM. The reaction was carried out at 37 ℃ and 300 rpm for 1 h with shaking to obtain the first treatment solution.

[0061] S232. Add 2×termination solution to the first treatment solution and let it stand at 25 ℃~37 ℃ for 1 h~1.5 h to obtain the second treatment solution.

[0062] The volume ratio of the first treatment solution to the termination solution is 1:1. This volume ratio facilitates sampling and addition.

[0063] The stop solution includes 2.0 mg / mL to 5.0 mg / mL trypsin and 2×Tris buffer containing 2 mM to 6 mM NAM.

[0064] S233. The fluorescence intensity of the second treatment solution is detected at an excitation wavelength of 360 nm and an emission wavelength of 460 nm. The activity of sirtuin deacylation enzyme in the test cells is determined based on the fluorescence intensity of the second treatment solution.

[0065] The tool used to detect fluorescence intensity is an ELISA reader. It should be noted that the tool for detecting fluorescence intensity is not limited to an ELISA reader; other tools capable of detecting fluorescence intensity, such as a fluorometer, can also be used.

[0066] In one specific example, BL21 lysis buffer transformed with blank plasmid was used as a negative control, and BL21 lysis buffer transformed with wild-type pTEV5-sirtuin plasmid was used as a positive control.

[0067] Studies have found that fluorescence intensity is directly proportional to the deacetylation activity of sirtuin protein. Therefore, this proportional relationship can be used to quantitatively detect the deacetylation activity of sirtuin. For example, a standard curve method can be used for quantitative detection.

[0068] It should be noted that after obtaining the desired sirtuin mutant with the desired deacetylation activity, the clones with significant changes in enzyme activity can be sequenced, analyzed, and summarized to obtain the corresponding mutation site information, and to predict and verify the deacetylation active site of the sirtuin protein.

[0069] Based on the current controlled mutation frequency of 1-4 bases / kb, constructing a mutant library with 10-fold coverage (screening 2,000-6,000 clones) can screen for sirtuin amino acid sites in all key regions, with the mutant library containing 2,000-6,000 clones.

[0070] The above-described method for screening sirtuin mutants is a simple, high-throughput, and reproducible method for screening artificial sirtuin deacylation enzymes. Random point mutation fragments encoding sirtuin protein DNA were obtained using error-prone PCR, recombinant plasmids were constructed and transformed into *E. coli* to obtain a sirtuin protein mutant library. Then, using optimized mild cell lysis buffer, the heterologously expressed sirtuin protein mutants in 96-well plates were lysed to obtain crude enzyme solution. Finally, the deacylation activity of the sirtuin mutants was detected in situ using an AMC-based fluorescent group release method. Therefore, this method mainly includes three steps: library construction, lysis, and detection. High-throughput screening of sirtuin protein mutants can be achieved by inducing sirtuin protein production through 96-well plate culture and using a microplate reader for fluorescence detection. The main advantages of this method are its simplicity and the optimized cell lysis buffer that allows for the direct lysis and release of sirtuin synthesized in vivo, which can then be detected by AMC fluorescence. Furthermore, this method is universal, enabling screening of different sirtuins for enzyme activity, not limited to specific functions performed by sirtuin under specific conditions. More importantly, this method combines error-prone PCR and AMC fluorescence, achieving a seamless connection between bacterial protein expression, lysis, and detection, making high-throughput screening of artificial sirtuin mutants possible. Subsequent sequencing of sirtuin mutants reveals mutation sites, allowing analysis of the relationship between site mutations and changes in enzyme activity, and prediction and verification of key sites for sirtuin deacylation activity.

[0071] AMC fluorescence detection is often used to detect the activity of a single sirtuin enzyme, or to screen for corresponding substrates and inhibitors of sirtuin through high-throughput in vitro enzyme activity detection. However, many sirtuin proteins cannot be expressed and purified in vitro, and direct lysis and release of sirtuin after in vivo synthesis often leads to the inactivation of subsequent enzymes, requiring protein purification processes before enzyme activity detection. This application uses cell lysis buffer to gently lyse sirtuin mutants, and the resulting lysis products can be used for AMC fluorescence detection of sirtuin deacylation enzyme activity without purification. The operation is simple and can screen for the enzyme activity of different sirtuins, not limited to the specific functions of sirtuin under specific conditions.

[0072] Currently, site studies of sirtuin protein either involve extensive molecular biology experiments for screening and verification, which are time-consuming and labor-intensive, or rely on protein structure analysis, which has very low throughput. Therefore, the development of a high-throughput mutant screening method based on enzyme activity detection is particularly important. This invention organically combines error-prone PCR for library construction with AMC fluorescence assay for enzyme activity detection. A frequency-controllable random mutant library is obtained through molecular cloning, and enzyme activity information is obtained in situ after protein expression. This constructs a complete sirtuin mutant screening system that is simple, reliable, and has high throughput. It enables a simple and high-throughput method to screen and discover deacylation activity regulatory sites of sirtuin protein, providing a foundation for subsequent sirtuin structure and function studies.

[0073] This method screens sirtuin enzyme activity mutants, performs in situ expression and activity determination in *E. coli*, eliminating the cumbersome protein purification and transfer processes, making it very simple. Furthermore, different acylated peptides can be used to test the different deacylated sirtuin enzyme activities, making this method applicable for screening different sirtuins and possessing universality. Moreover, this method, combined with error-prone PCR and AMC fluorescence assay, allows for the simultaneous determination of multiple proteins in large batches, providing quantitative results. In summary, compared to other methods, this study's method possesses advantages such as simplicity, universality, and high throughput.

[0074] One embodiment of this application also provides a sirtuin mutant, prepared by the above-described sirtuin mutant screening method. This sirtuin mutant can be used to modify deacylation enzyme activity.

[0075] The wild-type sirtuin is obtained by mutation at least one of the following sites: alanine at position 76, phenylalanine at position 91, histidine at position 147, cysteine ​​at position 155, and proline at position 185.

[0076] Furthermore, one of the following mutations occurs at position 76 of the alanine: A76P or A76V.

[0077] One of the following mutations occurs at position 91, phenylalanine: F91L or F91S.

[0078] One of the following mutations occurs at histidine position 147: H147L or H147Y.

[0079] The cysteine ​​residue at position 155 undergoes one of the following mutations: C155R, C155S, or C155Y.

[0080] One of the following mutations occurs at position 185 of the proline: P185L or P185T.

[0081] The following is a specific embodiment.

[0082] Unless otherwise specified, the reagents and instruments used in the examples are conventionally selected in the art. Experimental methods not specifying particular conditions in the examples are typically performed under standard conditions, such as those described in literature, books, or recommended by the reagent kit manufacturer. All reagents used in the examples are commercially available.

[0083] Example 1: Obtaining a library of random point mutants Taking the Salmonella-derived sirtuin protein STM1221 as an example, random point mutations were performed on a specific site region (V43-N240) to obtain a library of random point mutants with 1-3 mutated amino acids. The specific procedures are as follows: Previous studies have confirmed that the sirtuin protein STM1221 has high deacetylase activity. Through sequence alignment, the V43-N240 segment was selected as a potential active site. This gene was constructed into the Kan-resistant pET28a-STM1221 plasmid. Using the first primer pair (sequences shown in SEQ ID No. 1~SEQ ID No. 2), EP-PCR (error-prone PCR) was used to amplify DNA fragments of the STM1221 critical region with 2-4 point mutations in each product (referred to as mutant fragments). Simultaneously, using pTEV5-STM1221 as a template, the second primer pair (sequences shown in SEQ ID No. 3~SEQ ID No. 4) was used to amplify the STM1221 fragment excluding the critical region along with the expression vector (referred to as vector fragments) using a high-fidelity enzyme, and the template was digested with DpnI. Gel electrophoresis imaging was performed on the mutant fragments and the backbone fragments. See the gel electrophoresis images of the mutant fragments and the backbone fragments for details. Figure 3 . Figure 3The images show gel electrophoresis diagrams of the PCR products of the fragment and vector. Band 1 represents the mutant fragment, band 2 represents the vector fragment, and band 3 is a 1.1 kb standard. Primers used for PCR are detailed in Table 1. The EP-PCR system formulation is detailed in Table 2.

[0084] Subsequently, the mutant fragment and vector fragment were ligated using recombinase, transformed into DH5α competent cells, and positive clones (target clones) were selected using Amp resistance screening. Approximately 10 clones were selected and sequenced to verify the presence of random point mutations at 2-4 sites in the critical region. See sequencing results for details. Figure 4 ,from Figure 4 It can be seen that 8 out of 9 clones had random point mutations at 1-4 sites. Subsequently, a mixed plasmid was extracted from DH5α plaques and transformed into BL21. BL21 clones that successfully grew on Amp plates were randomly selected for sequencing, and the mutation results were consistent with expectations.

[0085] Table 1 Primer sequence list used for cloning construction

[0086] Table 2 EP-PCR system formulation

[0087] Example 2: In situ expression of the STM1221 mutant library and acquisition of proteins (1) After obtaining the STM1221 random mutant library in BL21, all clones were transferred to each well of a 96-well plate and cultured in Amp-resistant LB liquid medium at 37°C and 800 rpm overnight. Then, the saturated bacterial culture was transferred 1:20 to a new 96-well plate and cultured for another 1.5-2 h. When the OD reached 0.4, IPTG was added to a final concentration of 0.3 mM and protein expression was induced at 25°C. After 16 h, the plate was centrifuged at 4000 rpm and 4°C for 10 min to obtain the precipitate. Then, 10 μL of cell lysis buffer (0.5%~2% non-denaturing detergent and pH 7.6, 25 mM Tris-HCl buffer) was added to each well and shaken at 300 rpm for 10 min to obtain the cell lysis product. Then, the plate was centrifuged at 4000 rpm and 4°C for 10 min to obtain the lysis supernatant containing the target sirtuin protein. The lysis supernatant was then subjected to gel electrophoresis imaging.

[0088] (2) Following step (1) of this embodiment, the bacterial culture of *E. coli* BL21 induced by transformation with pTEV5-SIRT2 plasmid was lysed to obtain a lysate supernatant containing SIRT2 protein, and the lysate supernatant was subjected to gel electrophoresis imaging. See [link to gel electrophoresis image of lysate supernatant]. Figure 5 , Figure 5The SIRT2 protein is taken as an example. Figure 5 In the image, band 1 is the marker; bands 2 and 3 are protein bands from the supernatant of lysis products induced by 0 mM IPTG; and bands 4 and 5 are protein bands from the supernatant of lysis products induced by 0.3 mM IPTG for 16 h. Figure 5 It can be seen that the supernatant of the BL21 cell lysis products induced by IPTG can clearly show the target band of SIRT2, proving that this method can release the intracellular protein, namely sirtuin, into the supernatant.

[0089] (3) Add AMC-peptide to each well of the 384-well plate. Ac The substrate reaction solution (10 μL) consisted of 2 μL of 10×Tris buffer (0.5 M Tris-HCl, pH 8.0, 1.37 M NaCl, 27 mM KCl, 10 mM MgCl2) and 1 μL of 20 mM NAD+. + 0.8 μL 5 mM AMC-peptide Ac 6.2 μL ddH2O. Then, add 10 μL of STM1221 or SIRT2 protein solution diluted with ddH2O or lysis buffer, bringing the total reaction volume to 20 μL. The final Tris concentration is 50 mM, and the NAD... + The final concentrations were 1 mM for the peptide, 200 μM for the sirtuin protein, and 5 μM for the sirtuin protein. After reacting at 37 ℃ and 300 rpm for 1 h with shaking, 20 μL of 2× stop solution (2.0 mg / mL trypsin, 4 mM NAM in 2× Tris buffer) was added to each well, and the reaction was incubated at 25 ℃ for 1.5 h. Subsequently, fluorescence intensity was detected using a microplate reader at 360 nm excitation and 460 nm emission wavelengths. A reaction system without sirtuin served as a negative control. See [link to results] for details. Figure 12 . Figure 12 The graph shows the effect of the lysis buffer on the enzyme activity of STM1221 and SIRT2.

[0090] from Figure 12 It can be seen that the fluorescence intensity of sirtuin after reaction with the peptide in ddH2O and lysis buffer is comparable, indicating that the lysis buffer in this embodiment does not affect the enzyme activity of sirtuin.

[0091] Example 3 utilizes AMC-peptide Ac Detection of deacetylation activity of STM1221 mutant library The mutant library obtained in Example 2 yielded approximately 80 mutant proteins per 96-well plate. Therefore, by increasing the colony count, a total of 1000 STM1221 mutant proteins were obtained from 12 96-well plates. The subsequent testing used AMC-ARK... Ac The peptide (i.e., the AMC-labeled peptide modified by acetylation) was synthesized by Anhui Guoping Pharmaceutical Co., Ltd.

[0092] To determine whether the lysis buffer affected protease activity, BL21 cells transformed with wild-type STM1221 were first used for lysis and enzyme activity assays. BL21 bacteria were lysed using the lysis buffer used in Example 2, and the deacetylases were used to detect deacetylases activity. Figure 6 As shown, direct AMC fluorescence detection was performed on the lysate. However, the lysate from the negative control group BL21 also reacted with the peptide to produce fluorescence, but the reaction ceased after heat inactivation, indicating that other enzymes in the BL21 cell debris may interfere. Furthermore, only the supernatant from centrifuged lysate was used for AMC fluorescence detection. Only the lysate from BL21 transformed with STM1221 reacted with the AMC peptide to produce fluorescence. For detailed fluorescence detection results of the reaction between BL21 lysate and peptide, please refer to [link to relevant documentation]. Figure 6 . Figure 6 Figure a shows the reaction results of whole-cell lysate with AMC peptides, and Figure b shows the reaction results of the supernatant of the lysate with AMC peptides. The formulation of the AMC fluorescence detection system is detailed in Table 3.

[0093] Table 3 Formulation of AMC Fluorescence Detection System

[0094] Existing methods exist for in vitro detection of the activity of purified sirtuin protein using synthesized AMC substrates. This study also compared two methods using wild-type STM1221. 10 μL of reaction solution containing the AMC peptide was added to each well of a 384-well plate, including 2 μL of 10×Tris buffer (0.5 M Tris-HCl, pH 8.0, 1.37 M NaCl, 27 mM KCl, 10 mM MgCl2), and 1 μL of 20 mM NAD+. + 0.8 μL 5 mM AMC-peptide Ac6.2 μL ddH2O was added. Then, 10 μL of purified sirtuin protein or the supernatant containing the protein lysis product from the previous step was added. Cell lysis was performed using 2 L of E. coli BL21, and the final lysis yielded at least 1 mL of 100 μM sirtuin protein. If the culture system is scaled down to a 96-well plate, 200 μL of bacterial culture will yield at least 10 μL of 1 μM protein. Therefore, purified STM1221 protein with an initial concentration of 1 μM or 5 μM was selected as a control. Because SIRT2 protein also has a strong deacetylation ability, purified SIRT2 or BL21-SIRT2 lysis product was added as a control. The total reaction volume was 20 μL, and the final peptide concentration was 200 μM. The reaction was carried out at 37℃ with shaking at 300 rpm for 1 h. Next, 20 μL of 2× stop solution (2.0 mg / mL trypsin, 4 mMNAM in Tris assay buffer) was added to each well, and the reaction was incubated at 25 °C for 1.5 h. Afterwards, fluorescence intensity was detected using a microplate reader at 360 nm excitation and 460 nm emission wavelengths. The results are shown in Table 4. Figure 7 As shown in Table 4, the values ​​of each mutant detected by AMC fluorescence are presented, using a 96-well plate as an example. Figure 7 Fluorescence detection results of the reaction between purified sirtuin protein or sirtuin-containing cell lysate supernatant and substrate.

[0095] Table 4

[0096] from Figure 7 It can be seen that STM1221 or SIRT2 purified by 1 μM or 5 μM showed fluorescence detection after reacting with the substrate, and the lysis buffer containing these proteins showed stronger fluorescence after reacting with the peptide. In addition, the BL21 lysis product transformed with blank plasmid did not react with the substrate, which proves the feasibility of detecting enzyme activity by cell lysis. Moreover, this method significantly reduces the workload compared with protein purification and in vitro detection, and also provides conditions for high-throughput screening.

[0097] The fluorescence intensity of the reaction product was directly proportional to the deacetylation activity of sirtuin. Using BL21 lysis buffer transformed with the blank plasmid as a negative control and BL21 lysis buffer transformed with the wild-type pTEV5-STM1221 plasmid as a positive control, the STM1221 mutant library in 12 wells of the aforementioned database was analyzed to preliminarily quantify the deacetylation activity of STM1221, yielding 480 clonal strains with significant alterations in enzyme activity. Examples of fluorescence detection results for the mutant library are detailed below. Figure 8 , Figure 8In the image, shades of gray represent fluorescence intensity. The last column shows the BL21 negative control (4 wells) and the WT STM1221 positive control (4 wells).

[0098] Example 4: Sequencing of the STM1221 mutant yielded key active site information and verification. STM1221 clones with deacetylase activity reduced by >80% were selected for sequencing. Approximately 500 clones were obtained. After excluding clones with more than 5 single-clonal point mutations, 176 mutation sites were obtained.

[0099] Table 5 shows some mutant sites and fluorescence detection results, representing single-point clones detected by sequencing in the same batch of experiments. From the established mutant library containing approximately 1800 clones, two single-point mutants, STM1221-H147L and STM1221-H147Y, were obtained through random mutation. Their enzyme activity fluorescence detection results are as follows: Figure 9 As shown, the deacetylation ability decreased to a level comparable to the negative control. The H147 site in STM1221 has been confirmed as an absolutely conserved site determining deacetylation activity in sirtuin proteins; therefore, the successful mutation at this site and the detection of complete loss of enzyme activity demonstrates the feasibility of this method for screening mutants. In addition, other mutants such as STM1221-C176G / A212V were obtained, with significantly reduced enzyme activity. The enzyme activity and site information of the mutant library were analyzed using fluorescence detection; the results are detailed in [link to results]. Figure 9 , Figure 9 This is for fluorescence detection of enzyme activity and site information in mutant libraries. Figure 9 In the figure, figure a shows the results of fluorescence detection of the mutant library, and figure b shows the results of repeated fluorescence detection of the mutant library. Figure 9 As can be seen, sequencing of clones with significantly reduced fluorescence yielded point mutation information. These clones were then re-induced to express in BL21, and fluorescence was detected upon lysis. The results are as follows: Figure 9 As shown in b, consistent with the first detection, the fluorescence detection of mutants has high accuracy and good repeatability.

[0100] Table 5. Site and fluorescence detection results of unit point mutants.

[0101] Analysis of the sirtuin enzyme activity regulatory sites was performed; the results are detailed in [link to results]. Figure 10 . Figure 10This is a diagram illustrating the regulatory sites of sirtuin enzyme activity. For the same degree of deacetylation activity change, the site causing the activity decrease due to a single mutation has a greater determining effect on the deacetylation activity of STM1221 than the site causing the activity change due to three mutations. Therefore, by assigning scores to the mutation sites based on their weights, the amino acid site scores were obtained; the higher the score, the greater the determining effect of the active site. Based on the site information, it can be inferred that amino acids such as W67, V75, and H227 in STM1221 may play a decisive role in its deacetylation activity. In subsequent work, through sequence alignment, corresponding amino acid sites were identified in other typical sirtuins, such as human SIRT2 and SIRT5, and E. coli cobB, for mutation, and the active sites were verified.

[0102] Specifically, in the established mutant library containing approximately 1800 clones, fluorescence detection revealed a large number of clones with significantly reduced deacetylation activity. Sequencing of these clones yielded site mutation information in key regions. Considering only cases where a single clone contains four or fewer point mutations, this mutation site information was compiled and scored according to their weights: a clone with one point mutation received 1 point, and a clone with four point mutations received 0.25 points per site. The statistical results are as follows. Figure 10 Five sites scored above 4.5, including the His-147 site, which is absolutely conserved in all sirtuin proteins and determines sirtuin deacylation activity. This further confirms the feasibility of our random point mutation library construction and high-throughput fluorescence screening method for identifying active sites. Besides the Ala-76 amino acid, which has been mentioned in structural reports of CobB and Sir2Tm proteins and may be related to the decrotonylation of CobB and the depropionylation activity of Sir2Tm, the other three sites, Phe-91, Cys-155, and Pro-185, have no corresponding sites reported in other sirtuins. Therefore, the method in this application is of great significance for efficiently discovering novel potential active sites.

[0103] Example 5 Sirtuins are enzymes with diverse deacylation activities, capable of removing not only acetyl groups from lysine residues but also succinyl, crotonyl, and long-chain fatty acyl groups. They are used to synthesize AMC-peptides with different acyl group modifications on lysine residues. AcyThe peptide can be used to detect other deacylation activities of sirtuin protein, obtaining information on other deacylation active sites. Therefore, the method used in this application is not limited to the detection of deacetylation activity, but can also be applied to the detection of other deacylation activities of sirtuin, and all should be included within the scope of protection of this invention.

[0104] In this embodiment, succinylated AMC-peptide was synthesized using the same method as in the previous embodiments. Su The peptide, which reacts with cell lysis products transformed with the sirtuin protein expression vector, also produces fluorescence. See details for the assay results. Figure 11 . Figure 11 Cell lysis buffer and AMC-peptide Ac or AMC-peptide Su Fluorescence detection results of peptide reactions. For example... Figure 11 As shown, the BL21 lysis buffer transformed with the blank plasmid pUC19 did not react with any acylated peptides. The multifunctional STM1221 reacted with two peptides to produce fluorescence, while the deacetylase SIRT2 lysis buffer only reacted with AMC-peptide. Ac The reaction, and the cleavage products of desuccinylation enzyme SIRT5 with AMC-peptide Su The reaction produced strong fluorescence, demonstrating the reaction specificity of these substrates, which can be used to detect the activity of other enzymes, characterize other mutant libraries, and obtain information on other deacylated active sites.

[0105] The embodiments described above are merely illustrative of several implementations of the present invention, and while the descriptions are relatively specific and detailed, they should not be construed as limiting the scope of the invention patent. It should be noted that those skilled in the art can make various modifications and improvements without departing from the concept of the present invention, and these all fall within the protection scope of the present invention. Therefore, the protection scope of this invention patent should be determined by the appended claims.

Claims

1. A method of screening for sirtuin mutants, comprising, Includes the following steps: A library of sirtuin mutants was constructed using error-prone PCR techniques. Each mutant in the sirtuin mutant library was lysed using cell lysis buffer, solid-liquid separation was performed, and the lysis supernatant was collected. The cell lysis buffer included: a non-denaturing detergent and a buffer solution with pH 7-8. The sirtuin deacylation activity of the lysate supernatant was determined by high-throughput AMC fluorescence method to obtain the sirtuin mutant with the desired deacylation activity; The process of constructing the sirtuin mutant library using an initial sirtuin gene, which includes linked critical and non-critical region segments, and which encodes the Salmonella-derived sirtuin protein STM1221, includes the following steps: Error-prone PCR was performed using a plasmid carrying the initial sirtuin gene as a template to obtain a mutant fragment. The mutant fragment is the critical region fragment in which a point mutation has occurred. The plasmid carrying the initial sirtuin gene is a plasmid carrying the critical region fragment, which is the gene fragment corresponding to V43~N240 of the sirtuin protein STM1221. Using a plasmid carrying an expression vector as a template, PCR amplification was performed under the action of a high-fidelity enzyme to obtain an expression vector fragment. The expression vector is used to express the initial sirtuin. The expression vector fragment is composed of expression and replication elements for expressing the sirtuin protein. The resistance gene of the plasmid carrying the expression vector is different from that of the plasmid carrying the initial sirtuin gene. The mutant fragment and the expression vector fragment are recombined and ligated, and then transferred into host cells. The mutation frequency of 1-4 bases / kb and the theoretical coverage of 10 times are controlled to obtain the sirtuin mutant library. The sirtuin mutant library includes mutants obtained by mutating at least one of the following sites of the initial sirtuin: phenylalanine at position 91, cysteine ​​at position 155, and proline at position 185.

2. The method of screening for sirtuin mutants according to claim 1, wherein, Error-prone PCR was performed using the first primer pair, the sequences of which are shown in SEQ ID No. 1 to SEQ ID No.

2.

3. The method of screening for sirtuin mutants according to claim 1, wherein, In the step of using a plasmid carrying an expression vector as a template for PCR amplification under the action of a high-fidelity enzyme, a second primer pair is used for PCR amplification, and the sequence of the second primer pair is shown in SEQ ID No. 3~SEQ ID No.

4.

4. The method of screening for sirtuin mutants according to claim 1, wherein, A mutant library with 10-fold theoretical coverage was constructed based on a mutation frequency of 1-4 bases / kb. Amino acid sites in the key region of sirtuin were screened. The mutant library contained 2,000-6,000 clones.

5. The method for screening sirtuin mutants according to claim 1, characterized in that, In the step of lysing each mutant in the sirtuin mutant library, cell lysis buffer is used for lysis. The cell lysis buffer includes: 0.5% to 2% by mass of non-denaturing detergent, 100mM to 200mM of salts, and a buffer solution with a pH of 7 to 8. The volume ratio of the cell lysis buffer to the bacterial culture containing the cells to be tested is 1:20 to 1:

40. The lysis temperature is 20℃ to 30℃, and the lysis time is 10 min to 20 min.

6. The method for screening sirtuin mutants according to claim 1, characterized in that, The step of determining the sirtuin deacylation activity of the lysis supernatant using AMC fluorescence method includes: The AMC peptide reaction solution was mixed with the lysis supernatant and reacted at 37°C and 200 rpm to 300 rpm for 1 h to obtain the first treatment solution. The AMC peptide reaction solution contained AMC peptides with acyl modification and the final concentration of the AMC peptides was 100 μM to 500 μM. Add 2× stop solution to the first treatment solution and let it stand at 25 ℃~37 ℃ for 1 h~1.5 h to obtain the second treatment solution. The stop solution includes 2.0 mg / mL~5.0 mg / mL trypsin and 2×Tris buffer containing 2 mM~6 mM NAM. The fluorescence intensity of the second treatment solution was detected at an excitation wavelength of 360 nm and an emission wavelength of 460 nm. The activity of sirtuin deacylation enzyme in the test cells was determined based on the fluorescence intensity of the second treatment solution.

7. The method for screening sirtuin mutants according to claim 6, characterized in that, The acyl modification in the AMC peptide segment with acyl group modification is acetyl modification, succinyl modification, myristyl modification, nonanoyl modification, or long-chain fatty acyl modification.

8. The method for screening sirtuin mutants according to claim 6, characterized in that, The AMC peptide is a peptide with lysine acylation modification and AMC labeling, protected by a BOC group.

Citation Information

Patent Citations

  • Method for screening and testing activity of lysine propionylation removal enzyme and butyrylation removal enzyme

    CN102140494A

  • Protease screening methods and proteases identified thereby

    CN107630011A